These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20195035)

  • 21. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.
    Piga A; Gaglioti C; Fogliacco E; Tricta F
    Haematologica; 2003 May; 88(5):489-96. PubMed ID: 12745268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
    Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
    Tsironi M; Polonifi K; Deftereos S; Farmakis D; Andriopoulos P; Moyssakis I; Aessopos A
    Eur J Haematol; 2005 Oct; 75(4):355-8. PubMed ID: 16146544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of deferiprone on urinary zinc excretion in multiply transfused children with thalassemia major.
    Bartakke S; Bavdekar SB; Kondurkar P; Muranjan MN; Manglani MV; Sharma R
    Indian Pediatr; 2005 Feb; 42(2):150-4. PubMed ID: 15767711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
    Wu KH; Chang JS; Tsai CH; Peng CT
    Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early cardiac iron overload in children with transfusion-dependent anemias.
    Fernandes JL; Fabron A; Verissimo M
    Haematologica; 2009 Dec; 94(12):1776-7. PubMed ID: 19815835
    [No Abstract]   [Full Text] [Related]  

  • 27. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.
    Telfer PT; Warburton F; Christou S; Hadjigavriel M; Sitarou M; Kolnagou A; Angastiniotis M
    Haematologica; 2009 Dec; 94(12):1777-8. PubMed ID: 19815834
    [No Abstract]   [Full Text] [Related]  

  • 28. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
    Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
    Poggi M; Sorrentino F; Pugliese P; Smacchia MP; Daniele C; Equitani F; Terlizzi F; Guitarrini MR; Monti S; Maffei L; Losardo A; Pasin M; Toscano V
    Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF; Peng CT; Wu KH; Tsai CH
    Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
    Moayedi B; Gharagozloo M; Esmaeil N; Maracy MR; Hoorfar H; Jalaeikar M
    Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
    Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract]   [Full Text] [Related]  

  • 33. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.
    Borgna-Pignatti C; Cappellini MD; De Stefano P; Del Vecchio GC; Forni GL; Gamberini MR; Ghilardi R; Piga A; Romeo MA; Zhao H; Cnaan A
    Blood; 2006 May; 107(9):3733-7. PubMed ID: 16373663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy.
    Sharma R; Seth A; Chandra J; Gohain S; Kapoor S; Singh P; Pemde H
    Paediatr Int Child Health; 2016 Feb; 36(1):22-7. PubMed ID: 25311879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.
    DivakarJose RR; Delhikumar CG; Ram Kumar G
    Indian J Pediatr; 2021 Apr; 88(4):330-335. PubMed ID: 32661609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.
    Pennell DJ; Berdoukas V; Karagiorga M; Ladis V; Piga A; Aessopos A; Gotsis ED; Tanner MA; Smith GC; Westwood MA; Wonke B; Galanello R
    Blood; 2006 May; 107(9):3738-44. PubMed ID: 16352815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
    N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.